Nektar Therapeutics Announces its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC)

— Results demonstrate NKTR-255’s differentiated pharmacologic profile versus precomplexed IL-15 agonists, supporting its potential as a potent immunotherapy agent — SAN FRANCISCO , May 18, 2021 /PRNewswire/ —  Nektar Therapeutics  (Nasdaq: NKTR) today announced the publication of preclinical


Get every new post delivered right to your inbox.

Original Source